Replies to post #1604 on RespireRx Pharmaceuticals Inc (RSPI)

[alertmeipp]

We already down to 2.8 because of this dosing uncertainty which I think is way overdone.

"The dosing uncertainty" we have now is far less risk than "the clinical hold uncertainty" we have before yet the share price doesn't reflect that.

The market seems always assume the worst case and that's how I made my money.

Keep the faith.

[alertmeipp]

gfp927z - what do u get this idea from?

"For all we know, the dosing regimen used in the successful ADHD Phase 2a trial isn't allowed under the current dosing restrictions (800 mg BID for 3 weeks)."


Also, the PR states "In agreeing to the lifting of the hold, Cortex committed to an FDA specified dose range for CX717"

It didn't mention about the limitation on "dosing duration"??

TIA